Gilead Sciences stock slides 1.64% and underperforms competitors
Updated
Updated · MarketWatch · May 7
Gilead Sciences stock slides 1.64% and underperforms competitors
6 articles · Updated · MarketWatch · May 7
The shares closed at $134.06 on Thursday, snapping a five-day winning streak, as the S&P 500 fell 0.38% and the Dow dropped 0.63%.
Gilead ended 14.77% below its 52-week high of $157.29 reached on 11 February, while Johnson & Johnson and Pfizer also fell and Abbott Laboratories rose 0.82%.
Trading volume reached 7.9 million shares, above the 50-day average of 6.0 million, indicating heavier activity during the broader market sell-off.
Why did Gilead's stock fall despite beating profit estimates and raising its 2026 sales outlook?
Is Gilead's $16B bet on oncology a visionary move or a costly distraction from its legal troubles?